22.25
-1.26 (-5.34%)
| Penutupan Terdahulu | 23.50 |
| Buka | 23.30 |
| Jumlah Dagangan | 149,344 |
| Purata Dagangan (3B) | 797,635 |
| Modal Pasaran | 724,199,616 |
| Harga / Pendapatan (P/E TTM) | 17.52 |
| Harga / Pendapatan (P/E Ke hadapan) | 3.43 |
| Harga / Jualan (P/S) | 1.01 |
| Harga / Buku (P/B) | 2.34 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 5 Nov 2026 |
| Margin Keuntungan | 6.61% |
| Margin Operasi (TTM) | 13.71% |
| EPS Cair (TTM) | 1.22 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 22.70% |
| Pertumbuhan Pendapatan Suku Tahunan (YOY) | -91.30% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 411.94% |
| Nisbah Semasa (MRQ) | 1.08 |
| Aliran Tunai Operasi (OCF TTM) | 198.44 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 341.32 M |
| Pulangan Atas Aset (ROA TTM) | 7.95% |
| Pulangan Atas Ekuiti (ROE TTM) | 19.23% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Drug Manufacturers - Specialty & Generic (US) | Bercampur | Bercampur |
| Drug Manufacturers - Specialty & Generic (Global) | Bercampur | Bercampur | |
| Stok | Collegium Pharmaceutical, Inc. | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 3.5 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 2.0 |
| Penilaian Relatif | -5.0 |
| Kesihatan Kewangan | 2.5 |
| AI Insight | NA |
| Purata | 1.06 |
|
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic. |
|
| Sektor | Healthcare |
| Industri | Drug Manufacturers - Specialty & Generic |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 1.69% |
| % Dimiliki oleh Institusi | 117.12% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
AI Analisis Teknikal
Buka tab Teknikal untuk menjana analisis terkini.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |